AstraZeneca Raises FY23 Guidance, Now Expects Increase By A Mid-Single-Digit Percentage (Previously Low-To-Mid Single-Digit); Sees Core EPS Increase By A Low Double-Digit To Low-Teens Percentage (Previously High Single-Digit To Low Double-Digit)
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca has raised its FY23 guidance, now expecting a mid-single-digit percentage increase in total revenue and a low double-digit to low-teens percentage increase in core EPS. The previous guidance was for a low-to-mid single-digit increase in total revenue and a high single-digit to low double-digit increase in core EPS.
November 09, 2023 | 8:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's updated FY23 guidance indicates higher expected revenue and EPS growth, which could positively impact the company's stock price in the short term.
AstraZeneca's updated guidance indicates that the company expects higher revenue and EPS growth than previously forecasted. This suggests that the company's financial performance may be stronger than previously expected, which could make the stock more attractive to investors and potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100